Amvuttra® (vutrisiran)

Published: March 27, 2024 in Drug

Full Name	Amvuttra® (vutrisiran)
Drug	Amvuttra
Manufacturer	Alnylam Pharmaceuticals, Inc.
Route of Administration	Subcutaneous
Site of Care	Home or Healthcare Facility
Approved Indication	The treatment of: The polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults The cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits
Disease	Hereditary ATTR amyloidosis (hATTR) – Polyneuropathy (PN) Cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM)
Therapeutic Area	Neurology, Cardiology
Enrollment Form Link	Start Form
Phone Number	800-372-9581
Product Website	amvuttrahcp.com
Patient Resources	Amyloidosis Research Consortium